Chapter 3: Pharmacodynamics or What the Drug Does to the Body

Pharmacodynamics or What the Drug Does to the Body details the structural and functional characteristics of the four primary receptor families: G protein-coupled receptors (GPCRs), ligand-gated ion channels, membrane-bound enzymes, and nuclear receptors. A significant portion of the chapter is dedicated to GPCRs, describing their seven-transmembrane domains and their interaction with heterotrimeric G proteins consisting of alpha, beta, and gamma subunits. The narrative explains how these interactions regulate second messengers such as cyclic AMP (cAMP), inositol triphosphate (IP3), diacylglycerol (DAG), and intracellular calcium to modify cellular function. The summary also distinguishes between membrane receptors, which act quickly via kinase phosphorylation or ion flux, and intracellular nuclear receptors (such as steroid receptors), which translocate to the nucleus to alter gene transcription. Key quantitative concepts are thoroughly explored, including the law of mass action, receptor affinity, and the dissociation constant (Kd). The chapter differentiates between drug potency (the dose required for a specific effect, often measured as ED50) and efficacy (the maximal response a drug can produce). It further categorizes drugs based on intrinsic activity, distinguishing between full agonists, partial agonists, inverse agonists, and antagonists. The distinction between competitive antagonists, which shift dose-response curves to the right without affecting maximal response, and noncompetitive antagonists, which reduce maximal efficacy, is clearly outlined. Additionally, the text covers receptor regulation mechanisms, such as desensitization (tachyphylaxis), down-regulation, and up-regulation, explaining how these processes contribute to drug tolerance. Finally, the chapter contrasts graded dose-response relationships, which measure continuous physiological changes, with quantal dose-response relationships, which track all-or-none effects in a population. These concepts are used to define critical safety metrics, including the therapeutic index and the certain safety factor, which compare therapeutic doses against toxic or lethal doses to determine a drug's margin of safety.